Xilio Therapeutics (XLO) Competitors $0.90 -0.04 (-4.38%) (As of 10:26 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends XLO vs. GOSS, CKPT, ELDN, PEPG, ATOS, NLTX, PBYI, DRUG, MCRB, and IVAShould you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Gossamer Bio (GOSS), Checkpoint Therapeutics (CKPT), Eledon Pharmaceuticals (ELDN), PepGen (PEPG), Atossa Therapeutics (ATOS), Neoleukin Therapeutics (NLTX), Puma Biotechnology (PBYI), Bright Minds Biosciences (DRUG), Seres Therapeutics (MCRB), and Inventiva (IVA). These companies are all part of the "pharmaceutical preparations" industry. Xilio Therapeutics vs. Gossamer Bio Checkpoint Therapeutics Eledon Pharmaceuticals PepGen Atossa Therapeutics Neoleukin Therapeutics Puma Biotechnology Bright Minds Biosciences Seres Therapeutics Inventiva Gossamer Bio (NASDAQ:GOSS) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability. Does the MarketBeat Community believe in GOSS or XLO? Gossamer Bio received 139 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Xilio Therapeutics an outperform vote while only 66.23% of users gave Gossamer Bio an outperform vote. CompanyUnderperformOutperformGossamer BioOutperform Votes15166.23% Underperform Votes7733.77% Xilio TherapeuticsOutperform Votes1275.00% Underperform Votes425.00% Do institutionals & insiders have more ownership in GOSS or XLO? 81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 5.0% of Gossamer Bio shares are owned by company insiders. Comparatively, 5.2% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, GOSS or XLO? Gossamer Bio has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500. Is GOSS or XLO more profitable? Gossamer Bio's return on equity of -127.28% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gossamer BioN/A -127.28% -22.12% Xilio Therapeutics N/A -211.50%-80.31% Which has stronger valuation and earnings, GOSS or XLO? Gossamer Bio is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer BioN/AN/A-$179.82M-$0.32-2.17Xilio TherapeuticsN/AN/A-$76.40M-$1.72-0.52 Does the media favor GOSS or XLO? In the previous week, Gossamer Bio had 4 more articles in the media than Xilio Therapeutics. MarketBeat recorded 4 mentions for Gossamer Bio and 0 mentions for Xilio Therapeutics. Gossamer Bio's average media sentiment score of 0.59 beat Xilio Therapeutics' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media. Company Overall Sentiment Gossamer Bio Positive Xilio Therapeutics Neutral Do analysts prefer GOSS or XLO? Gossamer Bio presently has a consensus price target of $9.20, indicating a potential upside of 1,225.46%. Xilio Therapeutics has a consensus price target of $4.00, indicating a potential upside of 344.44%. Given Gossamer Bio's higher probable upside, equities research analysts clearly believe Gossamer Bio is more favorable than Xilio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryGossamer Bio beats Xilio Therapeutics on 10 of the 14 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XLO vs. The Competition Export to ExcelMetricXilio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.56M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.524.9789.5613.60Price / SalesN/A371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book1.8810.306.976.33Net Income-$76.40M$153.61M$119.04M$225.93M7 Day Performance-5.99%-1.73%-1.78%-0.96%1 Month Performance11.22%-7.26%-3.59%1.06%1 Year Performance-18.18%31.10%31.64%26.59% Xilio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XLOXilio Therapeutics1.9025 of 5 stars$0.90-4.4%$4.00+344.4%-21.6%$39.56MN/A-0.5273GOSSGossamer Bio4.4297 of 5 stars$0.69-0.3%$9.20+1,225.5%-16.9%$157.28MN/A-2.18180Gap UpCKPTCheckpoint Therapeutics3.4927 of 5 stars$3.42+1.2%$12.00+250.9%+62.5%$153.97M$100,000.000.0010Analyst RevisionELDNEledon Pharmaceuticals2.9405 of 5 stars$3.82-0.8%$16.00+318.8%+210.5%$151.50MN/A0.0010Analyst ForecastAnalyst RevisionPEPGPepGen2.457 of 5 stars$4.59+4.3%$14.67+219.5%-5.6%$149.63MN/A0.0072Analyst ForecastATOSAtossa Therapeutics1.2137 of 5 stars$1.19-1.3%$6.75+469.6%+62.2%$149.07MN/A-5.458Analyst DowngradeAnalyst RevisionNLTXNeoleukin TherapeuticsN/A$15.33-11.0%N/A+30.5%$144.07MN/A-4.9390High Trading VolumePBYIPuma Biotechnology4.4141 of 5 stars$2.85+0.4%$7.00+145.6%-27.0%$139.91M$235.60M5.92185Analyst ForecastDRUGBright Minds Biosciences0.8622 of 5 stars$31.25-4.3%N/A+2,513.4%$138.44MN/A0.00N/AMCRBSeres Therapeutics3.6801 of 5 stars$0.81-0.5%$5.08+527.6%-16.1%$138.30M$126.32M0.00233Analyst UpgradeIVAInventiva3.0751 of 5 stars$2.58-5.8%$14.00+442.6%-31.9%$135.40M$18.91M0.00100News CoverageGap Down Related Companies and Tools Related Companies GOSS Competitors CKPT Competitors ELDN Competitors PEPG Competitors ATOS Competitors NLTX Competitors PBYI Competitors DRUG Competitors MCRB Competitors IVA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XLO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
